The Lancet OncologyOvjeren akaunt

@TheLancetOncol

The Lancet Oncology is the global leader in clinical oncology publishing peer-reviewed research and reviews, comment, news, and Commissions. IF=35.386.

London, NYC, Boston, Beijing
Vrijeme pridruživanja: lipanj 2009.

Tweetovi

Blokirali ste korisnika/cu @TheLancetOncol

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @TheLancetOncol

  1. Prikvačeni tweet

    Clinical picture quiz: What is the next best step in treatment? See thread for presentation and image.

    Prikaži ovu nit
    Poništi
  2. Poništi
  3. Policy review: recommendations from the Consortium on international standards for the analysis of and endpoints in

    Poništi
  4. Online first: longterm results of the phase 3 New EPOC trial: systemic with or without in patients with resectable

    Poništi
  5. Very excited to launch a new Commission on childhood cancer — see you there?

    Poništi
  6. Poništi
  7. Clinical picture quiz: 74yo man with malignant pleural presents with worsening visual symptoms over 2weeks. MRI of the orbits reveals a new left orbital mass within the rectus muscle and encasing the optic nerve. What is the next best step in treatment?

    Prikaži ovu nit
    Poništi
  8. Poništi
  9. Online first: plus versus placebo in patients with resected, BRAFV600-mutant, stage III : exploratory biomarker analyses from the phase 3 COMBI-AD trial

    Poništi
  10. proslijedio/la je Tweet
    30. sij

    Two NEW modelling studies: Cervical cancer could be eliminated in countries worst affected by the disease, and 62 million women’s lives could be saved by 2120: 1) 2)

    Prikaži ovu nit
    Poništi
  11. Poništi
  12. Poništi
  13. See the inspiration for our Feb issue cover: Transcriptomic signatures related to the paradox in patients with clear cell renal cell carcinoma: a cohort study Read the article here:

    Prikaži ovu nit
    Poništi
  14. The February issue is now online. See for papers on , , Belantamab mafodotin for multiple , for grading, and more!

    Prikaži ovu nit
    Poništi
  15. proslijedio/la je Tweet
    31. sij
    , , i još njih 7
    Poništi
  16. proslijedio/la je Tweet

    Top pick of 2019 #8 Gene signatures of quiescent cells reveal mesenchymal shift and interactions with niche microenvironment. Read the full paper from Drs Friedel and Zou labs here ->

    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet

    Phosphorylated Rasal2 facilitates breast cancer progression. Get notified when papers like this are published. Register for content alerts from 's

    Poništi
  18. proslijedio/la je Tweet
    30. sij

    NEW viewpoint—Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors Free to read w/ reg

    @wwierda @MDAndersonNews @LeukemiaMDA
    Poništi
  19. proslijedio/la je Tweet
    29. sij

    Our February issue is online now, featuring trials on transplantation, Waldenström macroglobulinemia, & AML, updates on GVHD & tumour-lysis syndrome, art & pain in , disease in Africa & more!

    Prikaži ovu nit
    Poništi
  20. proslijedio/la je Tweet
    29. sij

    As part of the campaign on child & adolescent health & ahead of , our Editorial discusses the first global analysis of funding for childhood cancer research & calls for its consideration as a political priority

    , , i još njih 2
    Prikaži ovu nit
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·